SHANGHAI, Aug. 25, 2015 /PRNewswire/ -- WuXi
PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D
capability and technology platform company serving the
pharmaceutical, biotechnology, and medical device industries, and
Lee's Pharmaceutical Holdings Ltd. ("Lee's Pharm," Hong Kong
Exchange Stock Code: 0950), a research-based biopharmaceutical
company headquartered in Hong Kong
with 20 years of operations in China, today announced that the two companies
have signed an agreement whereby WuXi's Laboratory Testing Division
(LTD) will be the exclusive supplier of laboratory testing services
for Lee's Pharm. These services will include LTD's entire
portfolio of discovery and IND/NDA package services, including
chemistry analytical services, in vitro and in vivo biology,
oncology, immunology, in vitro ADME, pharmacokinetic /
pharmacodynamic studies, toxicology, and clinical
bioanalysis. LTD will provide dedicated program management,
streamline project coordination across WuXi, and allocate the
necessary resources and R&D development efforts for Lee's Pharm
programs.
"We are delighted to become exclusive supplier of the broad range
of laboratory testing services for the drug discovery portfolio of
Lee's Pharm," said Dr. Ge Li,
Chairman and CEO of WuXi PharmaTech. "WuXi has been building
a comprehensive and integrated R&D enabling platform, and this
strategic collaboration is an example of delivering that platform
to serve our innovative partners."
"WuXi's impressive platform of lab testing services will allow our
compounds to advance seamlessly through discovery, preclinical, and
clinical development," commented Dr. Benjamin Li, Executive Director and CEO of Lee's
Pharm. "We are confident that this strategic partnership with
LTD will streamline and accelerate our drug discovery program."
About WuXi PharmaTech
WuXi PharmaTech is a leading open-access R&D capability and
technology platform company serving the pharmaceutical,
biotechnology, and medical device industries, with operations in
China and the United States.
As a research-driven and customer-focused company, WuXi PharmaTech
provides a broad and integrated portfolio of services throughout
the drug and medical device R&D process. WuXi is also
building a platform to provide clinical diagnostic services
directly to physicians and their patients globally. WuXi
PharmaTech's services are designed to assist its global partners in
shortening the cycle and lowering the cost of drug and medical
device R&D. WuXi's Laboratory Testing Division (LTD)
provides a comprehensive and integrated testing platform throughout
the drug discovery and development process. With operations
in both China and the U.S., it
provides services and solutions in chemical analysis, in vivo and
in vitro biology, oncology, immunology, drug metabolism and
pharmacokinetic / pharmacodynamic studies, toxicology, bioanalysis,
and medical device testing. WuXi PharmaTech's operating
subsidiaries are known as WuXi AppTec. For more information,
please visit: http://www.wuxiapptec.com.
About Lee's Pharmaceutical Holdings Limited
Lee's Pharmaceutical Holdings Limited (Lee's Pharm) is a
research-based biopharmaceutical company headquartered in
Hong Kong, with more than 20 years
of operation in China's
pharmaceutical industry. It is fully integrated, with a strong
organization in drug development, manufacturing, sales and
marketing. It has established extensive partnerships with more than
20 international companies and currently has 14 marketed products.
Lee's Pharm focuses on several key disease areas such as
cardiovascular diseases, oncology, gynecology, dermatology and
ophthalmology. The company's research and development program has
produced 30 product candidates resulting from internal R&D
efforts and collaborations with U.S., European and Japanese
companies, including promising compounds to treat liver cancer and
pulmonary hypertension. The mission of Lee's Pharm is to become a
successful biopharmaceutical group in Asia providing innovative products to fight
diseases and improve health and quality of life.
For more information, please contact:
WuXi PharmaTech
Ronald Aldridge (for
investors)
LaVoie HealthScience
+1-617-374-8800 x109
+1 617-792-2459
ir@wuxiapptec.com
Aaron Shi (for the media)
Director, Corporate Communications
WuXi PharmaTech
+86-21-5046-4362
pr@wuxiapptec.com
Lee's Pharm
Vivian Fung
Licensing & Regulatory Manager
+852-2314-1282
info@leespharm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/wuxi-pharmatech-to-be-exclusive-supplier-of-laboratory-testing-services-to-lees-pharm-300132797.html
SOURCE WuXi PharmaTech (Cayman) Inc.